Navigation Links
CONRAD receives $28.5M Gates Foundation grant for HIV prevention research
Date:11/30/2007

Arlington, VA (November 30, 2007) The CONRAD Program of the Eastern Virginia Medical School today announced that it has received a $28.5 million grant from the Bill & Melinda Gates Foundation to develop microbicides for HIV prevention. To date, the Gates Foundation has awarded a total of $65 million to CONRAD for microbicide research.

The award will support the development of new combination microbicides, research on novel and improved in vitro and small-animal models to test microbicide safety and efficacy, validation of clinical biomarkers and testing of the new microbicide candidates for clinical safety.

Despite setbacks in the HIV prevention field over the past year, the global effort to develop effective new prevention tools, including microbicides, must go on, said Henry Gabelnick, Executive Director of CONRAD. We are grateful for the continued support of the Gates Foundation, and we are inspired by its commitment to making real progress in global health.

Microbicides are topical substances used intravaginally to potentially prevent HIV infection. Effective microbicides could be an important HIV prevention option for women, who account for approximately half of all people living with HIV globally.

CONRAD has served as a resource for the microbicide field for the past twenty years, and in that capacity, has provided support for preclinical, early clinical research and Phase III clinical trials for several microbicide candidates, many of which were funded by the Gates Foundation and/or USAID. New microbicide candidates CONRAD is currently researching contain several ingredients with different types of activity against HIV. Dr. Gabelnick continued, Due to the multiple pathways involved in mucosal infection and the number of new infections attributable to viruses that contain drug resistance-associated mutations, development of a combination microbicide is likely to be important to achieve successful prevention of
'/>"/>

Contact: Annette Larkin
annettelarkin@rationalpr.com
703-772-6427
CONRAD
Source:Eurekalert

Page: 1 2

Related biology news :

1. Rutgers Genetics receives $7.8 million for autism research
2. Herr receives Heinz Award for Technology, the Economy and Employment
3. UCI receives $5M from Edwards Lifesciences
4. Yu receives research funding from the Wallace H. Coulter Foundation
5. UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC
6. UC Riverside biologist receives prestigious MacArthur Fellowship
7. UC Irvine receives $2.18M to explore nano advancements in DNA sequencing
8. Penn biochemist receives NIH New Innovators Award
9. NYUs Center for Genomics & Systems Biology receives $4.4 million NSF grant
10. Einstein researcher receives NIH grant to explore epigenetic regulation of the human genome
11. Alaska graduate program in sustainability receives $3.2 million award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... University researchers have received a $1.5 million federal ... account of their ecological footprint., Seven researchers in ... Resources, Biosystems Engineering, and USDA Agricultural Research Service ... elements central to farming and out of balance ...
... purification of drug components is a large hurdle facing ... that utilize proteins, which are notoriously difficult to separate ... for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer Polytechnic ... and improve an important protein purification process. ...
... new class of drug designed to target the hepatitis ... some of the HCV strains being treated exhibited signs ... of Florida State University biologists, chemists and biomedical researchers ... the drug-resistant HCV strains and the molecular-level mechanisms that ...
Cached Biology News:WSU researchers taking sustainability of organic farming to new level 2Purifying proteins: Rensselaer researchers use NMR to improve drug development 2Purifying proteins: Rensselaer researchers use NMR to improve drug development 3Hepatitis C virus faces new weapon from Florida State scientists 2Hepatitis C virus faces new weapon from Florida State scientists 3
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, announced ... University of Calgary in conjunction with co-authors from Kyoto ... validates the company,s ongoing clinical research using dermal sheath ... baldness. The paper entitled " Hair Follicle ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Reports Financial Results for the 12 Months Ended December ... A/S,(OMX: GEN) announced today results for the financial year ... (approximately USD 104 million) compared to,DKK 136 million (approximately ... of DKK 437 million (approximately USD 86 million).,This compares ...
... (OTC Bulletin Board: IMYN), a biotechnology firm that ... to,the biopharmaceutical SF-1019, has announced its results for ... the year ended December 31, 2007, the company ... in interest expense which,was funded from advances by ...
... Elbit Imaging Ltd.,(Nasdaq: EMITF ) ("EI" or ... year 2007., Transition to IFRS, Through ... been,prepared in accordance with generally accepted accounting principles ... provisions of Standard 29 of the Israeli,Accounting Standard ...
Cached Biology Technology:Genmab Announces Year End 2007 Financial Results 2Genmab Announces Year End 2007 Financial Results 3Genmab Announces Year End 2007 Financial Results 4Genmab Announces Year End 2007 Financial Results 5Immunosyn Corporation Announces 2007 Results, Files 10KSB 2Immunosyn Corporation Announces 2007 Results, Files 10KSB 3Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 2Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 3Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 4Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 5Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 6Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 7Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 8Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 9Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 10Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 11Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 12Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 13Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 14Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 15Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 16
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
Biology Products: